{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: Denmark Healthcare news", "home_page_url": "https://sharemaestro.com/newsreel/dk/healthcare/", "feed_url": "https://sharemaestro.com/newsreel/dk/healthcare/feed.json", "description": "Latest Healthcare company headlines from Denmark, newest first, with industry sections, source links and company research.", "language": "en", "items": [{"id": "source:69a4a7c7fbad651b7d48f5808fc27680e8ea0f4e38147e36a268caab830e0e29", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-stock-slips-pill-183832098.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-stock-slips-pill-183832098.html", "title": "Novo Nordisk Stock Slips as Pill Strategy Reframes Obesity Race", "content_text": "This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish obesity-drug giant behind Wegovy and Ozempic, slipped approximately 1% Thursday morning as CEO Mike Doustdar tried to reset the market's thinking about the obesity race. His pitch: stop treating Novo versus Eli Lilly (NYSE:LLY) like a winner-takes-all fight. The obesity market could top $100 billion annually by 2030, and different patients will want different drugs, delivery methods and trade-offs. For Novo, that is more than a talking point. It is the heart of the comeback story after Lilly's Zepbound grabbed moment", "date_published": "2026-08-13T18:38:32+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:b40ec17efd7608a9b538f7a45f663802bba7284e20cc8d0232feee1d3f8ceb2d", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisks-wegovy-fueled-rebound-172000772.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisks-wegovy-fueled-rebound-172000772.html", "title": "Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating?", "content_text": "Novo Nordisk (NYSE: NVO) posted strong first-quarter results and performed fairly well in the month that followed its first-quarter update. However, the company's most recent financial update, for the second quarter, erased much of those gains. In both cases, the market's reaction was largely driven by the performance of the Wegovy pill, the first oral GLP-1 approved for weight loss, which Novo Nordisk launched in the U.S. in January. The Wegovy pill beat expectations in the first quarter but came up short in the second. What does this mean for the company's prospects?Image source: The Motley ", "date_published": "2026-08-13T17:20:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:ec826990d2c6b2707cb2345a499149ef75cc010896670e707947cc069f7f222f", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-cpse-novo-b-151234003.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-cpse-novo-b-151234003.html", "title": "Novo Nordisk (CPSE:NOVO B) Sees New Pressure In Weight Loss Drugs", "content_text": "Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Novo Nordisk (CPSE:NOVO B) faces fresh competition as the UK's MHRA approves Eli Lilly's oral weight loss therapy Foundayo for use in the country. The approval adds a non injectable option alongside Novo Nordisk's GLP 1 based obesity drugs and could affect demand patterns if Foundayo is adopted in public healthcare settings. In the US, Amazon Pharmacy launches a new Medicare weight loss drug program priced at $50 per month that will include Novo Nordisk an", "date_published": "2026-08-13T15:12:34+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:0bca75b8bbc2a8fa3539987191796c6707dd6e26260af2ed0b559caa56026031", "url": "https://finance.yahoo.com/healthcare/articles/invitation-presentation-alk-first-six-140600422.html", "external_url": "https://finance.yahoo.com/healthcare/articles/invitation-presentation-alk-first-six-140600422.html", "title": "Invitation to the presentation of ALK\u2019s first six months (Q2) 2026 results on Thursday, 20 August 2026", "content_text": "ALK Abello ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) will publish its results for the first six months of 2026 in the morning on Thursday, 20 August 2026. Later on the same day, the company will host a presentation for investors and analysts at 1:30 p.m. CEST, where ALK's management will comment on the results for the first six months and the outlook and be available for questions. ALK will be represented by Peter Halling, President & CEO, Claus Steensen S\u00f8lje, CFO and Per Plotnikof, VP, Head of IR. Live audio webcast The meeting will be audio webcasted live and be available for replay on ALK's", "date_published": "2026-08-13T14:06:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ALK-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ALK-B", "name": "ALK-Abell\u00f3 A/S", "sentiment_url": "https://sharemaestro.com/sentiment/e5a5798a-6e6b-48ed-9dec-153219564368/"}]}}, {"id": "source:6a9ef7de3c3c4e0f617168c7947a2a19328d0a9ca572f6c5356f91e1ea48ad7b", "url": "https://finance.yahoo.com/markets/stocks/articles/zealand-pharma-zldpf-surpasses-q2-113502082.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/zealand-pharma-zldpf-surpasses-q2-113502082.html", "title": "Zealand Pharma A/S (ZLDPF) Surpasses Q2 Earnings and Revenue Estimates", "content_text": "Zealand Pharma A/S (ZLDPF) came out with quarterly earnings of $8.61 per share, beating the Zacks Consensus Estimate of a loss of $0.42 per share. This compares to earnings of $16.06 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of +2,150.00%. A quarter ago, it was expected that this company would post a loss of $1.57 per share when it actually produced a loss of $0.87, delivering a surprise of +44.59%. Over the last four quarters, the company has surpassed consensus EPS estimates four times. Zealand Pharma AS, w", "date_published": "2026-08-13T11:35:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ZEAL"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZEAL", "name": "Zealand Pharma A/S", "sentiment_url": "https://sharemaestro.com/sentiment/e3a2feb5-7bfa-4c30-b514-0833ab52f7d8/"}]}}, {"id": "source:1eb3095fe93db01645050a1f2e1ca1911617c4100f31d438c0109b8dc54343fc", "url": "https://finance.yahoo.com/markets/stocks/articles/zealand-pharma-cpse-zeal-stock-081006793.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/zealand-pharma-cpse-zeal-stock-081006793.html", "title": "Zealand Pharma (CPSE:ZEAL) Stock Looks Fairly Valued After Its 90% Five Year Run", "content_text": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Zealand Pharma stock has delivered a strong 90.3% return over the past five years, yet its low overall value score and current market multiples suggest the shares may now be closer to fairly priced than a clear bargain. Over five years, Zealand Pharma has returned 90.3%, which puts current buyers in a different position to those who entered earlier in the story. The recent $100 million royalty deal with Royalty Pharma can support funding for rusfertide and other priorities. Reliance on s", "date_published": "2026-08-13T08:10:06+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "ZEAL"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZEAL", "name": "Zealand Pharma A/S", "sentiment_url": "https://sharemaestro.com/sentiment/e3a2feb5-7bfa-4c30-b514-0833ab52f7d8/"}]}}, {"id": "source:4c47be21db0b869f236a4343c9b21e0fe0351201a70508d8b2df37feae0ef95f", "url": "https://finance.yahoo.com/healthcare/articles/zealand-pharma-announces-financial-results-050000185.html", "external_url": "https://finance.yahoo.com/healthcare/articles/zealand-pharma-announces-financial-results-050000185.html", "title": "Zealand Pharma Announces Financial Results for the First Half of 2026", "content_text": "Zealand Pharma Company announcement \u2013 No. 39 / 2026 Zealand Pharma Announces Financial Results for the First Half of 2026 A landmark first half defined by key milestones delivered for leading obesity assets, and a continued momentum building across all fronts of our Metabolic Frontier 2030 strategy. Announced decision to advance petrelintide into Phase 3 trials in H2 2026 following positive Phase 2 results, demonstrating double-digit weight loss with a tolerability profile largely comparable to placebo, supporting its potential to redefine the weight management experience for people living wit", "date_published": "2026-08-13T05:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "ZEAL"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZEAL", "name": "Zealand Pharma A/S", "sentiment_url": "https://sharemaestro.com/sentiment/e3a2feb5-7bfa-4c30-b514-0833ab52f7d8/"}]}}, {"id": "source:00065397cad77d25ae4cd46e71184695e7fc762987d47000af0a47dbe12b1e59", "url": "https://finance.yahoo.com/healthcare/articles/zealand-pharma-cpse-zeal-royalty-231634640.html", "external_url": "https://finance.yahoo.com/healthcare/articles/zealand-pharma-cpse-zeal-royalty-231634640.html", "title": "Zealand Pharma (CPSE:ZEAL) On Its Royalty Pharma Deal And The Fair Value Debate", "content_text": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Why Zealand Pharma stock is in focus after the Royalty Pharma deal Zealand Pharma (CPSE:ZEAL) has drawn fresh attention after agreeing to a US$100 million royalty purchase and sale deal with Royalty Pharma linked to rusfertide, a potential treatment for polycythemia vera. The agreement transfers Zealand Pharma's economic interests related to rusfertide, including potential future royalty rights. It also provides new funding that management plans to redeploy toward the company's key prior", "date_published": "2026-08-12T23:16:34+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Deals and strategy", "ZEAL"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZEAL", "name": "Zealand Pharma A/S", "sentiment_url": "https://sharemaestro.com/sentiment/e3a2feb5-7bfa-4c30-b514-0833ab52f7d8/"}]}}, {"id": "source:c207ea21f3bdcd74c15f6e961a5bd1e6f613db7c44a3abb1304c13ee62bab22b", "url": "https://finance.yahoo.com/healthcare/articles/demant-willf-q2-2026-earnings-230522384.html", "external_url": "https://finance.yahoo.com/healthcare/articles/demant-willf-q2-2026-earnings-230522384.html", "title": "Demant AS (WILLF) (Q2 2026) Earnings Call Highlights: Strong H1 Growth Fueled by Oticon Zeal ...", "content_text": "This article first appeared on GuruFocus. Revenue Growth: Group reported growth of 15% in H1 2026, with 7% organic growth and 10% acquisitive growth, primarily from KIND. Gross Margin: Increased by 1.1 percentage points, driven by strong ASP in hearing aids and the acquisition of KIND. EBIT before Special Items: DKK2.134 billion, corresponding to a margin of 16.5%, with 19% growth in local currencies. Cash Flow from Operations: DKK1.6 billion, a 6% increase compared to H1 2025. Hearing Aids Growth: 10% growth in Q2, driven by the full rollout of Oticon Zeal, with double-digit growth in North A", "date_published": "2026-08-12T23:05:22+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "DEMANT"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "DEMANT", "name": "Demant A/S", "sentiment_url": "https://sharemaestro.com/sentiment/459136d6-bfc4-4b76-8768-6b870260d4ca/"}]}}, {"id": "source:a6325fa22040e5dc4401ff094910036d501da606af5903010ffd9c8a18c147eb", "url": "https://finance.yahoo.com/healthcare/articles/royalty-pharma-zealand-pharma-enter-201000247.html", "external_url": "https://finance.yahoo.com/healthcare/articles/royalty-pharma-zealand-pharma-enter-201000247.html", "title": "Royalty Pharma and Zealand Pharma enter into rusfertide funding agreement for $100 million", "content_text": "Royalty Pharma plc NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $100 million in funding to Zealand Pharma in exchange for Zealand Pharma's economics related to rusfertide (PTG-300), a potential first-in-class therapy for polycythemia vera, a rare and chronic blood disorder. \"We are delighted to expand our relationship with Zealand Pharma through a second collaboration, supporting the company as it continues to advance its innovative pipeline of medicines for obesity and metabolic health,\" said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. \"This transaction underscores Royalty Pharma's role as a long-term, trusted partner to biopharma companies as they advance important medicines. Furthermore, we believe rusfertide has the potential to become a transformative treatment option for patients with polycythemia vera, and we look forward to its continued progress through regulatory review.\" \"We are very pleased to work with Royalty Pharma, a leading funder of life science innovation, on this strategic financial transaction,\" said Henriette Wennicke, Chief Financial Officer at Zealand Pharma. \"This agreement converts a future potential royalty stream into immediate capital that will be redeployed against future growth opportunities in line with our key strategic priorities under our Metabolic Frontier 2030 strategy.\" Rusfertide is a potential first-in-class therapy that mimics the action of hepcidin, a natural hormone that regulates iron homeostasis and red blood cell production. By targeting the underlying mechanism of iron dysregulation in polycythemia vera, rusfertide aims to reduce excess red blood cell production and help patients achieve sustained hematocrit control. Rusfertide is administered once weekly via subcutaneous self-injection and has been generally well-tolerated in clinical trials to date. The U.S. FDA has set a Prescription Drug User Fee Act (PDUFA) goal date for the New Drug Application (NDA) for rusfertide for the treatment of adults with polycythemia vera in the third quarter of 2026i and Takeda will be responsible for global commercialization. Transaction terms Under the terms of the royalty purchase and sale agreement, Royalty Pharma will provide $100 million to Zealand Pharma in exchange for its economic interests related to rusfertide, including rights to a 1% royalty on potential future global net sales of rusfertide and regulatory and commercial milestones. This consists of $50 million upon closing of the transaction with the remaining $50 million due upon the first anniversary of the closing of the agreement. Zealand Pharma will retain the right to a 0.25% royalty on annual net global sales of rusfertide greater than $1.5 billion, while Royalty Pharma will retain a 0.75% royalty on sales above $1.5 billion. Story Continues Background In June 2012, Zealand Pharma and Protagonist Therapeutics, Inc., entered into a research collaboration agreement to develop disulfide-rich peptides (DRPs). Under the agreement, Zealand Pharma was responsible for preclinical and clinical drug development of DRPs discovered under the collaboration. The research collaboration was terminated in 2014 and Protagonist's payment obligations to Zealand Pharma were clarified in a settlement agreement reached in 2021. In January 2024, Protagonist and Takeda entered into a worldwide license and collaboration agreement for rusfertide. Advisors Covington, Dechert, Jones Day and Kromann acted as legal advisors to Royalty Pharma. Goodwin acted as legal advisor to Zealand Pharma. About Royalty Pharma plc Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical compani", "date_published": "2026-08-12T20:10:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ZEAL"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZEAL", "name": "Zealand Pharma A/S", "sentiment_url": "https://sharemaestro.com/sentiment/e3a2feb5-7bfa-4c30-b514-0833ab52f7d8/"}]}}, {"id": "source:ad815a30e5c1a40c334a1b739029cbfe341e613cdf0512338a7f3ca45284208d", "url": "https://finance.yahoo.com/healthcare/articles/zealand-pharma-enters-usd-100-200500756.html", "external_url": "https://finance.yahoo.com/healthcare/articles/zealand-pharma-enters-usd-100-200500756.html", "title": "Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide", "content_text": "Zealand Pharma Company announcement \u2013 No. 38 / 2026 Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide Zealand Pharma will receive USD 100 million for the sale of its economic interests related to rusfertide, including royalty rights on the potential future global net sales of rusfertide. The agreement unlocks value from a non-core royalty entitlement for redeployment to Zealand Pharma's key strategic priorities. Copenhagen, Denmark, August 12, 2026 \u2013 Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), ", "date_published": "2026-08-12T20:05:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ZEAL"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZEAL", "name": "Zealand Pharma A/S", "sentiment_url": "https://sharemaestro.com/sentiment/e3a2feb5-7bfa-4c30-b514-0833ab52f7d8/"}]}}, {"id": "source:fef18f4e280685de7dbc6c50d1d93df3658df1ac06d7c1efcd63083fe71bf0e5", "url": "https://finance.yahoo.com/healthcare/articles/berenberg-cuts-novo-nordisk-lilly-172911933.html", "external_url": "https://finance.yahoo.com/healthcare/articles/berenberg-cuts-novo-nordisk-lilly-172911933.html", "title": "Berenberg Cuts Novo Nordisk as Lilly Takes the Oral Market", "content_text": "This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish drugmaker behind Wegovy and Ozempic, fell 2.23% intraday after Berenberg downgraded the stock to Hold from Buy, cutting its Copenhagen target to DKK 305 from DKK 325 and its ADR target to $47 from $50. Analyst Kerry Holford argues that the Wegovy pill upside her Buy rating was built on has already played out. Warning! GuruFocus has detected 3 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator. Berenberg and broader consensus now model around DKK 15 billion of Wegovy pill sales ", "date_published": "2026-08-12T17:29:11+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Analyst action", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:d90e2209731c3b9a7749d90bee2a2e591fe83a02bb6808379f75ca9198499298", "url": "https://finance.yahoo.com/markets/world-indices/articles/european-equities-traded-us-american-151123119.html", "external_url": "https://finance.yahoo.com/markets/world-indices/articles/european-equities-traded-us-american-151123119.html", "title": "European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading", "content_text": "European equities traded in the US as American depositary receipts were edging lower late Wednesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in", "date_published": "2026-08-12T15:11:23+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:de9e2e54cd03494c7c82bc314fdfb47b59256672fe30d3fa8a7dae8f56e46b3e", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-dips-4-month-151000827.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-dips-4-month-151000827.html", "title": "Novo Nordisk Dips 4% in a Month: How Should Investors Play the Stock?", "content_text": "Novo Nordisk NVO stock has declined 4% over the past month, with the company's second-quarter 2026 results emerging as the primary factor behind the recent weakness. Although NVO beat earnings and revenue estimates, investors remained concerned about underlying growth trends in its core obesity franchise. Notably, sales of injectable Wegovy for obesity were flat year over year in the second quarter, reflecting intensifying competition from rival Eli Lilly's LLY Zepbound injection and raising concerns about Novo Nordisk's ability to sustain momentum in the highly competitive GLP-1 market. Novo ", "date_published": "2026-08-12T15:10:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:3bd1d4ad8bb7d0f063cdf91911b1e774e17c9b40b57c311e89283e66b3dc6fec", "url": "https://finance.yahoo.com/healthcare/articles/pfizers-non-covid-portfolio-drive-150300621.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pfizers-non-covid-portfolio-drive-150300621.html", "title": "Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?", "content_text": "Pfizer's PFE business mix has changed significantly over the past few years. During the pandemic, the company became heavily dependent on COVID-19 products, Comirnaty (COVID-19 vaccine) and Paxlovid (oral antiviral). However, the company is gradually diversifying its portfolio through a combination of internal product launches, strategic acquisitions and the continued growth of several established brands. Pfizer's non-COVID portfolio is increasingly becoming the company's primary engine of growth, helping offset the sharp decline in Comirnaty and Paxlovid revenues. The latest second-quarter 2026 results provide particularly strong evidence of this transition. Pfizer's revenues excluding Comirnaty and Paxlovid increased 5% operationally, while its launched and acquired products grew 18% operationally. Pfizer also raised the midpoint of its 2026 revenue guidance by $500 million, with the company attributing roughly $1.5 billion of the improvement to better-than-expected performance of non-COVID products. Established Brands & New Products Drive PFE's Non-COVID Growth A key driving factor behind growth in non-COVID revenues has been the continued rise in sales of several established brands like Vyndaqel and alliance revenues from partner Bristol-Myers BMY for Eliquis. Some internally developed product launches are also contributing to its top-line growth. Key recent product launches include Abrysvo, the first RSV vaccine approved for older adults and for maternal immunization to protect infants; Zavzpret, a nasal spray CGRP antagonist for acute migraine treatment; Hympavzi, a once-weekly treatment for hemophilia A and B with inhibitors; Elrexfio, a BCMA-targeted bispecific antibody for relapsed or refractory multiple myeloma, and Litfulo for severe alopecia areata. PFE's Acquisitions Complement Internal R&D The company is also trying to rebuild its pipeline through acquisitions. Seagen, Metsera and Biohaven are the most significant strategic acquisitions in recent years and could turn out to be transformative opportunities for the company. A key acquired product that has become a significant contributor to revenue growth is Padcev, added from Seagen. In the second quarter, revenues from Pfizer's acquired products like Padcev, Nurtec (added from Biohaven) and others grew 25% operationally, when excluding the impact of certain one-time items in the same quarter a year ago. Pfizer's Pipeline Provides a Second Wave of Growth Pfizer is rebuilding its pipeline in oncology and obesity, which it believes can drive growth in 2028 and beyond. In obesity, Pfizer plans an extensive phase III program for berobenatide, its monthly GLP-1 receptor agonist added from last year's Metsera acquisition, in 2026. Pfizer plans to start more than 20 obesity studies in 2026, including 10 phase III studies for berobenatide for obesity and obesity-related comorbidities, including knee osteoarthritis and obstructive sleep apnea. Pfizer is targeting the first of a series of potential approvals for berobenatide in 2028. However, in the obesity space, Pfizer lags behind leaders like Eli Lilly LLY and Novo Nordisk NVO. Story Continues The currently available and highly popular weight loss GLP therapies, Eli Lilly's Zepbound and Novo Nordisk's Wegovy, are weekly injections. On the other hand, Pfizer's berobenatide starts off as a weekly injection and then switches to a monthly injection. Berobenatide is designed for monthly maintenance dosing. Pfizer is also advancing its oncology clinical pipeline across areas such as breast, thoracic, gastrointestinal and blood cancer. Several oncology candidates have entered late-stage development. Pfizer plans to start four pivotal studies for PF-08634404, a dual PD-1/VEGF inhibitor in-licensed from Chinese biotech 3SBio in 2025. Besides obesity and oncology, Pfizer is advancing candidates in migraine, hemophilia, vaccines, inflammation and immunology. Several of these programs could create additional growth opportunities ove", "date_published": "2026-08-12T15:03:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:075b73d293c7e70fcab278c37a05cfa686169b2d4b7e54589715f81be0413b7a", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-scores-major-win-190732274.html", "external_url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-scores-major-win-190732274.html", "title": "Eli Lilly Scores Major Win in Weight-Loss Drug Race", "content_text": "This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) has secured U.K. approval for its once-daily weight-loss pill Foundayo, giving the drugmaker its first regulatory win for the treatment outside the U.S. and escalating its obesity battle with Novo Nordisk. The approval expands Lilly's opportunity beyond injectable drugs such as Zepbound while giving patients a potentially simpler oral option in one of the pharmaceutical industry's fastest-growing markets. Warning! GuruFocus has detected 6 Warning Signs with INTC. Is LLY fairly valued? Test your thesis with our free DCF calculator. Lilly is one of the world's largest pharmaceutical companies, with diabetes and obesity treatments driving an increasing share of growth. Its portfolio includes injectable Mounjaro and Zepbound, while Foundayo, also known as orforglipron, extends its GLP-1 franchise into pills. Britain's Medicines and Healthcare products Regulatory Agency authorized Foundayo on Aug. 10 for weight management and Type 2 diabetes. The pill can be taken once daily at any time without food or water restrictions, potentially offering a convenience advantage for patients. The U.K. approval follows Foundayo's U.S. clearance on April 1. It also intensifies competition with Novo Nordisk, whose oral Wegovy received U.K. approval in June. Foundayo is still early in its commercial ramp, generating $98 million in second-quarter sales. But Lilly's broader obesity franchise is already powering extraordinary growth: companywide Q2 revenue jumped 48% to $23 billion, driven primarily by Mounjaro and Zepbound volume. Investor Takeaway The next question is how quickly Foundayo can translate regulatory approvals into meaningful sales. For investors, U.K. reimbursement will be critical. Although Foundayo is now approved, the MHRA says it is not currently available through the National Health Service, with NICE still needing to evaluate the treatment before broader NHS access. That makes reimbursement decisions, prescription growth and additional international approvals the key catalysts. If Foundayo gains traction alongside Zepbound rather than merely cannibalizing injections, Lilly could broaden the addressable GLP-1 population substantially. But slower uptake versus Novo Nordisk's competing pill, pricing pressure or limited reimbursement could temper the opportunity despite the regulatory momentum. View Comments", "date_published": "2026-08-11T19:07:32+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:e6b8fb8b7756e99aa4374c23943f6e0a9e8a1e41130e8092aada209c9a6372c1", "url": "https://finance.yahoo.com/markets/stocks/articles/capital-increase-genmab-result-employee-175300211.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/capital-increase-genmab-result-employee-175300211.html", "title": "Capital Increase in Genmab as a Result of Employee Warrant Exercise", "content_text": "Genmab A/S Company Announcement COPENHAGEN, Denmark; August 11, 2026 \u2013 Genmab A/S (Nasdaq: GMAB) will increase its share capital by 24,592 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the Company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 4,702 shares at DKK 1,334.50, 2,069 shares at DKK 1,362.50, and 17,821 shares at DKK 1,615.00. Proceeds to the Company are approximately DKK 37.9 million. The increase corresponds to approximately 0.04% of the Company's share capital. The new shares are ordinary shares without any special rights and are freely transferable negotiable instruments. The new shares give rights to dividends and other rights in relation to the company as of subscription. The new shares will be listed on Nasdaq Copenhagen after registration with the Danish Business Authority. The capital increase is expected to be finalized shortly. Pursuant to section 32 of the Danish Capital Markets Act No. 464 of May 1, 2026, it is hereby announced, that the total nominal value of Genmab A/S' share capital after the capital increase is DKK 62,377,844 which is made up of 62,377,844 shares of a nominal value of DKK 1 each, corresponding to 62,377,844 votes. About Genmab Genmab is an international biotechnology company dedicated to improving the lives of people with cancer and other serious diseases through innovative antibody medicines. For over 25 years, its passionate, innovative and collaborative team has advanced a broad range of antibody-based therapeutic formats, including bispecific antibodies, antibody-drug conjugates (ADCs), immune-modulating antibodies and other next-generation modalities. Genmab's science powers eight approved antibody medicines, and the company is advancing a strong late-stage clinical pipeline, including wholly owned programs, with the goal of delivering transformative medicines to patients. Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X. Contact: Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs T: +1 609 524 0065; E: mmp@genmab.com Andrew Carlsen, Vice President, Head of Investor Relations T: +45 3377 9558; E: acn@genmab.com This Company Announcement contains forward looking statements. The words \"believe,\" \"expect,\" \"anticipate,\" \"intend\" and \"plan\" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.comand the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward ", "date_published": "2026-08-11T17:53:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "GMAB"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GMAB", "name": "Genmab A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1a591078-2b4b-4c42-9ccb-8d5fba81165f/"}]}}, {"id": "source:1a3b32ef831d54b2e9784a1f1298c6f354cf649c962bf1f028b08bc2c2fc49d3", "url": "https://finance.yahoo.com/markets/stocks/articles/european-equities-traded-us-american-152616420.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/european-equities-traded-us-american-152616420.html", "title": "European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading", "content_text": "European equities traded in the US as American depositary receipts were tracking higher late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in", "date_published": "2026-08-11T15:26:16+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:f53eaa18aedf51372d662341409289f815d56c13511c52603faa6fe7cd092351", "url": "https://finance.yahoo.com/healthcare/articles/lilly-takes-weight-loss-pill-151241058.html", "external_url": "https://finance.yahoo.com/healthcare/articles/lilly-takes-weight-loss-pill-151241058.html", "title": "Lilly Takes Its Weight-Loss Pill Battle Overseas", "content_text": "This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the developer of Foundayo and Zepbound, has received U.K. approval for Foundayo, the first approval for the weight-loss medication outside of the U.S. The The strategy pits Lilly directly against Novo Nordisk's Wegovy tablet in one of Europe's biggest drug marketplaces.Foundayo will initially be provided by private prescription. Availability will be wider via the U.K.'s National Health Service, subject to a review of cost efficiency.Lilly is banking on convenience to help it catch up with Novo. You can take Foundayo with or without food. Wegovy should be taken on an empty stomach and you should not eat or drink anything for at least 30 minutes after taking it.That difference could significant as both companies look to grow the oral weight-loss market beyond people already on injectable medications. Foundayo achieved $98 million in sales in the U.S. during the second quarter, after launching in April.The U.K. approval is the first serious test of whether Lilly can make Foundayo a worldwide player rather than just another U.S. GLP-1 medication, for investors. View Comments", "date_published": "2026-08-11T15:12:41+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:97f6e7dd7967fab0fced2a61373648d8b2954f601c1b248325bdc8700e25ec1f", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-company-lly-vs-124416743.html", "external_url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-company-lly-vs-124416743.html", "title": "Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market?", "content_text": "The duopoly dominating the multi-billion-dollar GLP-1 weight-loss market has moved from pharmacy shelves to the federal courtroom. Novo Nordisk A/S (NYSE:NVO) filed a lawsuit in U.S. District Court in New Jersey against Eli Lilly and Company (NYSE:LLY) on July 21, accusing its primary rival of false advertising and unfair competition regarding television and digital campaigns for Zepbound and Mounjaro. While both pharmaceutical giants continue to deliver massive top-line growth, a look at their underlying fundamentals shows that one company is clearly pulling ahead in execution, clinical trials, and market expansion.Eli Lilly and Company (LLY) vs. Novo Nordisk A/S (NVO): Is Lilly Pulling Ahead in the $100 Billion Obesity Market? The Lawsuit: Misleading Ads vs. Scientific Evidence Novo Nordisk A/S (NYSE:NVO)'s legal action centers on commercial advertisements aired during major broadcasts and social media platforms. Novo Nordisk claims that Eli Lilly's promotional campaigns intentionally use outdated trial data to pit the highest approved doses of Lilly's tirzepatide (Zepbound/Mounjaro) against lower, older doses of Novo's semaglutide (Wegovy/Ozempic). Novo argues these ads create consumer confusion by omitting Novo's recently approved higher-dose versions, demanding a permanent injunction to pull the ads and force Lilly to launch a corrective campaign. Eli Lilly and Company (NYSE:LLY) fired back immediately, stating that its commercials are \"truthful,\" \"transparent,\" and grounded in direct scientific evidence. A spokesperson for Eli Lilly emphasized that the claims stem from the SURMOUNT-5 trial, which is a rigorous head-to-head clinical study directly comparing tirzepatide against semaglutide. Lilly asserted that rather than competing on product merits, Novo Nordisk is attempting to censor published trial results. Lilly confirmed it plans to defend itself \"vigorously\" in court. Q1 2026 Financial Comparison: Lilly Takes the Lead Both companies remain highly profitable, but Eli Lilly is currently demonstrating significantly faster top-line growth and stronger forward momentum based on their Q1 2026 financial results. Eli Lilly and Company (NYSE:LLY) Eli Lilly delivered exceptional growth in its Q1 2026 results, with revenue increasing 56% year-over-year to $19.8 billion. The growth was primarily driven by a 65% increase in sales volume, led by strong demand for its blockbuster GLP-1 medicines, Mounjaro and Zepbound. The company also reported a significant improvement in profitability, with net income reaching $7.4 billion, or $8.26 per share, compared with $2.8 billion, or $3.06 per share, in Q1 2025. Non-GAAP EPS surged 156% to $8.55, reflecting strong operating leverage and robust commercial execution. Story Continues Supported by accelerating demand, Eli Lilly raised its full-year 2026 revenue guidance by $2 billion, increasing its expected revenue range to $82.0 billion\u2013$85.0 billion. The company also lifted its non-GAAP EPS outlook to $35.50\u2013$37.00, signaling continued confidence in its growth trajectory. Novo Nordisk A/S (NYSE:NVO) Novo Nordisk delivered solid headline growth in Q1 2026, but its results reflected a more complex operating environment. Net sales increased 32% year-over-year in constant exchange rates (CER) to DKK 96.82 billion ($13.8 billion). However, this growth was significantly impacted by a $4.2 billion non-recurring provision reversal related to the U.S. 340B Drug Pricing Program. Excluding this one-time benefit, adjusted sales declined 4% at CER due to lower realized prices in the U.S., despite continued volume growth in GLP-1 products. Reported operating profit increased 65% in constant exchange rates to DKK 59.62 billion, although adjusted operating profit declined 6% at CER to DKK 32.86 billion, highlighting ongoing pricing and margin pressures. Commercially, Novo Nordisk continued to advance its obesity franchise with the successful U.S. launch of the Wegovy oral pill, which generated DKK 2.26 bi", "date_published": "2026-08-11T12:44:16+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:e4d66b03678950178928288d08a6264862d9514b7f771d77c5ec1fca253bc068", "url": "https://finance.yahoo.com/healthcare/articles/cloud-ai-today-novo-nordisk-123802779.html", "external_url": "https://finance.yahoo.com/healthcare/articles/cloud-ai-today-novo-nordisk-123802779.html", "title": "Cloud AI Today - Novo Nordisk Partners With AWS For AI-Driven Drug Discovery", "content_text": "Novo Nordisk has entered a strategic partnership with Amazon Web Services (AWS) to enhance drug discovery using artificial intelligence and cloud technologies. This collaboration includes establishing a co-innovation hub in London, which brings together AWS engineers, AI specialists, and Novo Nordisk's research and development teams to streamline the process of bringing new medicines to market. As part of this agreement, AWS becomes Novo Nordisk's preferred cloud provider and strategic AI partner, leveraging AWS's AI technologies to compress timelines from drug target identification to clinica", "date_published": "2026-08-11T12:38:02+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:a7d9ff2d0e4110674f81814d0a079c7ef4b4bdbaf3846ecc48044c626ddf7d81", "url": "https://www.nasdaq.com/articles/nvo-crosses-above-average-analyst-target-0", "external_url": "https://www.nasdaq.com/articles/nvo-crosses-above-average-analyst-target-0", "title": "NVO Crosses Above Average Analyst Target", "content_text": "In recent trading, shares of Novo-Nordisk AS (Symbol: NVO) have crossed above the average analyst 12-month target price of $47.48, changing hands for $47.73/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level. Analyst reaction may also depend on the fundamental business developments that may be responsible for driving the stock price higher \u2014 if things are looking up for the company, perhaps it is time for that target price to be raised. There are 10 different analyst ", "date_published": "2026-08-11T11:43:35+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Analyst action", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:b9c761b005c2ccc85568e4eabdb7719772386434822950f8b29a3ed646a289fd", "url": "https://finance.yahoo.com/markets/stocks/articles/bioharvest-sciences-inc-bhst-reports-111001198.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/bioharvest-sciences-inc-bhst-reports-111001198.html", "title": "BioHarvest Sciences Inc. (BHST) Reports Q2 Loss, Lags Revenue Estimates", "content_text": "BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.15 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -30.77%. A quarter ago, it was expected that this company would post a loss of $0.13 per share when it actually produced a loss of $0.11, delivering a surprise of +15.38%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. BioHarvest Sciences Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $8.84 million for the quarter ended June 2026, missing the Zacks Consensus Estimate by 10.51%. This compares to year-ago revenues of $8.52 million. The company has topped consensus revenue estimates just once over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. BioHarvest Sciences Inc. shares have lost about 59.5% since the beginning of the year versus the S&P 500's gain of 13.3%. What's Next for BioHarvest Sciences Inc.? While BioHarvest Sciences Inc. has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for BioHarvest Sciences Inc. was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Story Continues It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.11 on $11.51 million in revenues for the coming quarter and -$0.45 on $43.01 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 39% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Zealand Pharma A/S (ZLDPF), has yet to report results for the quarter ended June 2026. The results are expected to be released on August 13. This company is expected to post quarterly loss of $0.42 per share in its upcoming report, which represents a year-over-year change of -102.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Zealand Pharma A/S's revenues are expected to be $81.55 million, down 94.1% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report BioHarvest Sciences Inc. (BHST) : Free Stock Analysis Report Zealand Pharma A/S (ZLDPF) : Free Stock Ana", "date_published": "2026-08-11T11:10:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ZEAL"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ZEAL", "name": "Zealand Pharma A/S", "sentiment_url": "https://sharemaestro.com/sentiment/e3a2feb5-7bfa-4c30-b514-0833ab52f7d8/"}]}}, {"id": "source:856f1a890d1010a0718990119ff198749abb5e74843c64f49c772ee65baacdbd", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-vs-novo-nordisk-222158536.html", "external_url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-vs-novo-nordisk-222158536.html", "title": "Eli Lilly vs. Novo Nordisk: Which Company Is Better Positioned for America\u2019s New Drug Manufacturing Policies?", "content_text": "For years, investors have viewed Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) through one lens: the race to dominate the booming obesity-drug market. But Washington is beginning to shift the conversation. With the U.S. government pushing pharmaceutical companies to manufacture more medicines domestically and reduce dependence on overseas supply chains, manufacturing has become more of a competitive advantage than an operational consideration. That shift creates a new question for investors. If domestic manufacturing becomes a larger determinant of pricing, regulatory flexibility, and supply-chain resilience, which company is better positioned: the American manufacturer rapidly expanding its production network, or the Danish pharmaceutical giant racing to localize more of its U.S. supply chain?Is NanoViricides Inc. (NNVC) the Best Nanotech Penny Stock to Invest In? Bull Case Eli Lilly (NYSE:LLY) appears to have anticipated this policy direction well before it became a political priority. The company's U.S. capital expansion commitments total over $55 billion since 2020, and it has plans to break ground on a number of its recently announced American manufacturing sites this year. What makes those investments particularly significant is that they extend beyond simply producing more Mounjaro and Zepbound. Lilly (NYSE:LLY) is building manufacturing capabilities across multiple drug technologies, giving it flexibility to support future pipeline assets alongside today's blockbuster products. As obesity treatments evolve and new therapies move toward commercialization, that broader manufacturing platform could become a long-term strategic asset rather than merely a solution to current supply constraints. The policy environment also appears increasingly favorable. The Trump administration has encouraged pharmaceutical companies to expand domestic manufacturing through Most-Favored-Nation (MFN) pricing agreements and manufacturing commitments, while the FDA recently launched its PreCheck Pilot Program to accelerate regulatory engagement for companies building new U.S. drug manufacturing facilities. Lilly (NYSE:LLY) is already benefiting from that direction of travel. The company's Lebanon, Indiana manufacturing facility was among the first selected for the FDA's PreCheck program, potentially allowing manufacturing issues to be identified earlier in the regulatory process and reducing delays before commercial production begins. Novo Nordisk (NYSE:NVO), however, should not be viewed as starting from scratch. The company already operates substantial manufacturing facilities in Clayton, North Carolina, and has committed billions of dollars to expanding its U.S. production capabilities. Since three decades, the company has expanded nine times in North Carolina, invested nearly $6 billion dollars, built and upgraded two more facilities, and expanded its employee count from 50 to more than 2,000. Story Continues This is significant because the question is no longer whether Novo (NYSE:NVO) has U.S. manufacturing, because it clearly does. The more relevant question is whether it can localize enough of its production quickly enough to match Lilly's (NYSE:LLY) broader domestic manufacturing ecosystem. Bear Case The strongest argument against Lilly (NYSE:LLY) is that manufacturing scale alone does not guarantee attractive shareholder returns. While Lilly's (NYSE:LLY) expansion has strengthened its long-term strategic position, investors must eventually evaluate whether those factories generate returns commensurate with their cost. A manufacturing advantage becomes valuable only if it translates into sustained revenue growth, higher margins, or stronger competitive positioning. There is also a broader industry risk. The obesity market has moved from supply shortages toward rapid capacity expansion. Lilly (NYSE:LLY), Novo Nordisk (NYSE:NVO), and several other pharmaceutical companies are simultaneously investing billions of dollars into manufactu", "date_published": "2026-08-10T22:21:58+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:1ab483cdb822eca8bd11e3ca4e52d97708df8e1d0115e1c7cbabc6db033a6a77", "url": "https://finance.yahoo.com/healthcare/articles/orchestra-biomed-holdings-inc-obio-215506647.html", "external_url": "https://finance.yahoo.com/healthcare/articles/orchestra-biomed-holdings-inc-obio-215506647.html", "title": "Orchestra BioMed Holdings, Inc. (OBIO) Reports Q2 Loss, Misses Revenue Estimates", "content_text": "Orchestra BioMed Holdings, Inc. (OBIO) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.35. This compares to a loss of $0.5 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -8.57%. A quarter ago, it was expected that this company would post a loss of $0.4 per share when it actually produced a loss of $0.33, delivering a surprise of +17.5%. Over the last four quarters, the company has surpassed consensus EPS estimates two times. Orchestra BioMed Holdings, Inc., which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $0.09 million for the quarter ended June 2026, missing the Zacks Consensus Estimate by 32.31%. This compares to year-ago revenues of $0.84 million. The company has topped consensus revenue estimates two times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Orchestra BioMed Holdings, Inc. shares have added about 2.2% since the beginning of the year versus the S&P 500's gain of 13.3%. What's Next for Orchestra BioMed Holdings, Inc.? While Orchestra BioMed Holdings, Inc. has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Orchestra BioMed Holdings, Inc. was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Story Continues It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.37 on $0.12 million in revenues for the coming quarter and -$1.47 on $0.48 million in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 40% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. Another stock from the same industry, Zealand Pharma A/S (ZLDPF), has yet to report results for the quarter ended June 2026. The results are expected to be released on August 13. This company is expected to post quarterly loss of $0.42 per share in its upcoming report, which represents a year-over-year change of -102.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. Zealand Pharma A/S's revenues are expected to be $81.55 million, down 94.1% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Orchestra BioMed Holdings, Inc. (OBIO) : Free Stock Analysis Report ", "date_published": "2026-08-10T21:55:06+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ZEAL"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ZEAL", "name": "Zealand Pharma A/S", "sentiment_url": "https://sharemaestro.com/sentiment/e3a2feb5-7bfa-4c30-b514-0833ab52f7d8/"}]}}, {"id": "source:b263b513747f629033941085a27e5b35265b1bcea3fca24c8fcc4947fa9cfa00", "url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-vs-novo-nordisk-213923809.html", "external_url": "https://finance.yahoo.com/healthcare/articles/eli-lilly-vs-novo-nordisk-213923809.html", "title": "Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?", "content_text": "The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have spent the past three years comparing prescription growth, market share, and pipeline candidates as Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) compete for dominance in one of healthcare's fastest-growing markets. Yet another competitive advantage for investors to keep in mind is manufacturing. During the early stages of the GLP-1 boom, demand consistently exceeded supply. Shortages of Wegovy, Ozempic, Mounjaro, and Zepbound demonstrated that developing a breakthrough medicine is only part of the challenge. Companies must also manufacture those medicines reliably, expand production fast enough to meet demand, and build enough capacity to support the next generation of therapies. That raises an important question for investors. As the obesity market matures, will the competitive advantage belong to the company with the strongest drugs, or the one with the strongest manufacturing platform? A specialized research team in white lab coats working together on a breakthrough biotechnological discovery. Bull Case Eli Lilly (NYSE:LLY) increasingly appears to view manufacturing as a long-term competitive advantage rather than simply a production necessity. Over the past several years, the company has committed tens of billions of dollars to expanding its manufacturing footprint across the United States. Rather than concentrating on a single facility, Lilly (NYSE:LLY) is investing across multiple manufacturing technologies, including active pharmaceutical ingredients, injectable medicines, and advanced therapies. This broader approach could give the company flexibility not only to support current demand for Mounjaro and Zepbound but also to manufacture future pipeline assets as they reach commercialization. That flexibility may become increasingly valuable. Today's obesity market is dominated by injectable therapies, but Lilly's (NYSE:LLY) pipeline extends well beyond its current products. Building capacity across multiple technologies today reduces the likelihood that manufacturing becomes a bottleneck tomorrow. The strategy also creates optionality beyond obesity. Manufacturing assets developed for peptide medicines, biologics, and advanced therapies can potentially support a much broader pharmaceutical portfolio. In other words, Lilly (NYSE:LLY) is investing in infrastructure that could generate value long after today's GLP-1 supply constraints disappear. Story Continues Lilly's (NYSE:LLY) manufacturing strategy also reflects a broader shift in how pharmaceutical companies think about competitive advantage. Historically, manufacturing was viewed as a support function that followed successful drug development. In the obesity market, however, manufacturing capacity has become a prerequisite for commercial success. The companies capable of supplying enough medicine can continue gaining market share, while those constrained by production risk leave demand unmet regardless of clinical performance. Novo Nordisk's (NYSE:NVO) strategy is different but no less compelling. Novo has continued expanding a production network that already includes decades of expertise in peptide manufacturing. The company has invested heavily in expanding its Clayton, North Carolina campus while strengthening its fill-finish capabilities through the acquisition of former Catalent facilities. Since three decades, the company has expanded nine times in North Carolina, invested nearly $6 billion dollars, built and upgraded two more facilities, and expanded its employee count from 50 to more than 2,000. In addition to expanding its U.S. footprint, the company's manufacturing network remains more geographically diversified than Lilly's (NYSE:LLY), which has historically been an advantage from an operational perspective. This approach also emphasizes manufacturing experience rather than manufacturing scale alone. Producing complex biologic me", "date_published": "2026-08-10T21:39:23+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:ed286af6b6de07313445863cfd7aeb8c8cc507d3a2353012df48364b401ee7e8", "url": "https://finance.yahoo.com/m/db700a16-f71a-30fb-9e7e-c325c0d84078/hims-stock-falls-on-earnings..html", "external_url": "https://finance.yahoo.com/m/db700a16-f71a-30fb-9e7e-c325c0d84078/hims-stock-falls-on-earnings..html", "title": "Hims Stock Falls on Earnings. Why a Guidance Hike Isn\u2019t Enough.", "content_text": "Hims faces restructuring charges as it shifts its U.S. weight-loss business away from compounded GLP-1 medications. Continue Reading", "date_published": "2026-08-10T21:12:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:93d9edea299f9a52b4ae8bbdb3be8c375c59ecef0e32ebffb837c514c00bea5b", "url": "https://finance.yahoo.com/markets/stocks/articles/european-stocks-close-mixed-monday-153834840.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/european-stocks-close-mixed-monday-153834840.html", "title": "European Stocks Close Mixed in Monday Trading as Investors Monitor Middle East War Developments", "content_text": "The European stock markets closed mixed in Monday trading as investors continue to gauge development PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in", "date_published": "2026-08-10T15:38:34+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:4a81e75201b2b09ef5feb33aaac4d2a700ce6f406ee5f208e767a4f5bc08b72c", "url": "https://finance.yahoo.com/markets/stocks/articles/zealand-pharma-transactions-related-share-150000162.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/zealand-pharma-transactions-related-share-150000162.html", "title": "Zealand Pharma - Transactions related to share buy-back program (week 32, 2026)", "content_text": "Zealand Pharma Company announcement No. 37 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 32, 2026) Copenhagen, Denmark, August 10, 2026 \u2013 Zealand Pharma A/S (\"the Company\" or \"Zealand Pharma\") (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today reports transactions related to its share buy-back program (the \"Program\") for week 32 (August 3 - August 7, 2026). The Program is carried out in accordance with Article 5 of Regulation (EU) No 596/2014 (the Market Abuse Regulation, \"MAR\") and Commission Delegated R", "date_published": "2026-08-10T15:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "ZEAL"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ZEAL", "name": "Zealand Pharma A/S", "sentiment_url": "https://sharemaestro.com/sentiment/e3a2feb5-7bfa-4c30-b514-0833ab52f7d8/"}]}}, {"id": "source:d4a997611e99bc446034b28dc1f70a02e93aa3566bb24736a84a8d5453cff49e", "url": "https://finance.yahoo.com/m/228d5141-325a-32e3-b4da-3b347a2a5268/this-biotech%E2%80%99s-drug-could.html", "external_url": "https://finance.yahoo.com/m/228d5141-325a-32e3-b4da-3b347a2a5268/this-biotech%E2%80%99s-drug-could.html", "title": "This Biotech\u2019s Drug Could Treat Hot Flashes. The Stock Is Up 36% on Good News.", "content_text": "New data show a single dose of AbCellera\u2019s menopause treatment, ABCL635, reduces how often patients with menopause experience hot flashes. Continue Reading", "date_published": "2026-08-10T14:12:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:c108582154a7ac46f6f3a3b7763f7802d32a1c62db70017a6d2f9f5a2b91f7ac", "url": "https://finance.yahoo.com/healthcare/articles/pfizer-rises-almost-7-post-131700150.html", "external_url": "https://finance.yahoo.com/healthcare/articles/pfizer-rises-almost-7-post-131700150.html", "title": "Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock", "content_text": "Pfizer PFE stock has risen 6.9% since it announced second-quarter 2026 results on Aug. 4. Pfizer delivered a solid second quarter, beating estimates for both earnings and revenues. While earnings growth was flat year over year, revenues rose 1% on an operational basis. Strength in non-COVID products continued to offset declining sales of its COVID products, Comirnaty (COVID-19 vaccine - in partnership with BioNTech [BNTX]) and Paxlovid (oral antiviral). Excluding sales from BioNTech-partnered Comirnaty and Paxlovid, revenues increased 5% operationally. Pfizer also raised the lower end of its 2026 revenue guidance, backed by continued strong performance of its new and acquired products. The company now expects revenues between $60.5 billion and $62.5 billion, compared with the previous range of $59.5 billion to $62.5 billion. The adjusted earnings guidance was reaffirmed at $2.80-$3.00 per share. However, the guidance now absorbs a 10 cents per share charge related to its licensing deal with Chinese biotech Innovent Biologics that will be recorded in the third quarter of 2026. However, a single quarter's results are not so important for long-term investors. To make an informed decision on whether to buy, sell or hold the stock, it is important to evaluate the company's fundamentals by examining its key strengths and weaknesses. First, let's understand the negatives. Declining Sales of PFE's COVID Products During the pandemic, Pfizer generated extraordinary COVID-related sales from Comirnaty and Paxlovid. Those revenues have fallen sharply as the pandemic faded. Sales of Pfizer's COVID products, Comirnaty and Paxlovid, came down to around $11 billion in 2024 and $6.7 billion in 2025 from $56.7 billion in 2022. Sales of Comirnaty are declining due to a narrow recommendation for COVID vaccines in the United States, while Paxlovid is experiencing reduced demand from lower infection rates. In 2026, Pfizer expects COVID-related revenues of approximately $4 billion, down from its previous forecast of $5 billion and below $6.7 billion generated in 2025. The decline reflects the continued normalization of COVID-19 infection rates and lower demand for COVID products. Consistent with this trend, sales of both Comirnaty and Paxlovid declined significantly during the first half of 2026. PFE's LOE Headwinds Pfizer faces a significant patent cliff later this decade. Pfizer expects a significant negative impact on revenues from the loss of exclusivity (\"LOE\") cliff in the 2026-2030 period as several of its key products, including Eliquis, Ibrance, Xeljanz and Xtandi, face patent expirations. The LOE cliff is expected to hurt sales by approximately $1.1 billion in 2026, which is slightly lower than the prior expectation of $1.5 billion. Story Continues PFE's 2026 Financial Outlook Dull Pfizer's revenue and earnings guidance for 2026 indicates mostly flat to slightly negative year-over-year growth. Pfizer expects total revenues for 2026 to be between $60.5 billion and $62.5 billion. The range represents a slight decline from 2025 revenues of $62.6 billion due to lower revenues from COVID products, Comirnaty and Paxlovid, and loss of revenues from the upcoming patent cliff. In 2026, Pfizer expects adjusted earnings per share in the range of $2.80-$3.00, which represents a decline from the 2025 EPS of $3.22 due to the dilutive impact of 3SBio and Metsera deals, lower COVID revenues and higher taxes. However, not everything is going wrong at Pfizer. Let's see the positives. PFE's Non-COVID Portfolio Driving Its Next Phase of Growth Pfizer's business mix has changed significantly over the past few years. During the pandemic, the company became heavily dependent on COVID-19 products. However, the company is gradually diversifying its portfolio through a combination of internal product launches like Abrysvo, Zavzpret, Elrexfio, Hympavzi, Litfulo and others, strategic acquisitions like Seagen, Metsera and Biohaven and the continued growth of several es", "date_published": "2026-08-10T13:17:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:3c47b8ef3ab797724be0ddfe5eb202d239caee7fc93025f9971b079f4bb6097c", "url": "https://finance.yahoo.com/healthcare/articles/chemometec-enters-collaboration-agreement-roche-103200914.html", "external_url": "https://finance.yahoo.com/healthcare/articles/chemometec-enters-collaboration-agreement-roche-103200914.html", "title": "ChemoMetec enters collaboration agreement with Roche Diagnostics", "content_text": "Chemometec A/S ANNOUNCEMENT NO. 311 After entering a Letter of Intent with Roche Diagnostics in February 2026, aiming to pursue a collaboration with the goal of creating synergies between the parties' solutions in the field of bioprocess monitoring, ChemoMetec and Roche Diagnostics have today entered a collaboration agreement. The agreement covers the development of a connection kit between the Roche-owned Cedex\u00ae Bio Analyzer and the ChemoMetec-owned Xcytomatic\u00ae 30 (XM30) cell counting analyzer, as well as aspects of the subsequent commercialization of the connectivity solution. Roche will be ", "date_published": "2026-08-10T10:32:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "CHEMM"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CHEMM", "name": "ChemoMetec A/S", "sentiment_url": "https://sharemaestro.com/sentiment/c6fa1a66-3bae-423c-92f1-f441f7ac2399/"}]}}, {"id": "source:92f6f2489bfc0f28da4db81b3bc4426ce09adcfab1a3dc475311c3dd38c47ec9", "url": "https://finance.yahoo.com/healthcare/articles/veru-reports-fiscal-2026-third-103000378.html", "external_url": "https://finance.yahoo.com/healthcare/articles/veru-reports-fiscal-2026-third-103000378.html", "title": "Veru Reports Fiscal 2026 Third Quarter Financial Results and Phase 2b PLATEAU Clinical Trial Progress", "content_text": "Veru Inc. -- Phase 2b PLATEAU clinical trial of enobosarm and semaglutide combination for high quality weight loss is fully enrolled with 239 patients \u2013 -- Phase 2b PLATEAU clinical trial interim analysis and results on track for calendar Q1 2027-- -- In June 2026 Company announced a clinical supply agreement with Novo Nordisk for its Phase 2b PLATEAU clinical trial -- -- In August 2026 Company announced USPTO notice of allowance for key U.S. patent for enobosarm and semaglutide; when issued, U.S. patent protection until at least October 2044 -- -- Company to host conference call and webcast today at 8:00 a.m. ET \u2013 MIAMI, FL, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases, today announced financial results for its fiscal 2026 third quarter ended June 30, 2026, and provided an update on progress of its clinical development programs. \"We are extremely pleased with the continued enobosarm progress during this past quarter,\" said Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru Inc. \"We reached full enrollment of the Phase 2b PLATEAU clinical trial and entered into a clinical supply agreement with Novo Nordisk for the Phase 2b PLATEAU clinical trial.* In addition, we received from the USPTO a notice of allowance for a key U.S. patent for enobosarm with semaglutide for high quality weight loss which when issued, will provide U.S. patent protection until at least October 2044.\" Dr. Steiner added: \"We believe these accomplishments mark important milestones in advancing enobosarm as a potential important combination therapy with GLP-1 receptor agonists. There is a significant unmet medical need to make weight reduction more tissue selective by maximizing fat loss while preserving lean mass, physical function, and bone mineral density for the highest quality weight reduction especially in older patients who have low muscle reserves and obesity. I want to thank both the patients and the investigators for their enthusiasm to expeditiously reach full enrollment for this very important study. We remain on track to achieve the near-term milestone of reporting the interim analysis results from the Phase 2b PLATEAU clinical trial in the first quarter of calendar year 2027.\" Obesity Program Evaluating enobosarm in combination with GLP-1 RA for higher quality weight reduction in older patients with obesity Story Continues Fully Enrolled Phase 2b PLATEAU Clinical Study The Phase 2b PLATEAU clinical trial is a double-blind, placebo-controlled study to evaluate the effect of enobosarm 3mg on total body weight, fat mass, lean mass, physical function, bone mineral density and safety in older patients (age \u2265 65 years) who have obesity (BMI \u2265 35) and are initiating semaglutide treatment for weight reduction. During the past quarter, the Company exceeded its Phase 2b PLATEAU clinical trial targeted full enrollment of 200 patients by enrolling 239 patients. The Phase 2b PLATEAU study is designed to assess the ability of enobosarm treatment to break through the weight loss plateau observed in patients with obesity receiving GLP-1 RA treatment by preserving muscle mass and physical function to achieve clinically meaningful incremental weight reduction by 68 weeks. The primary efficacy endpoint of the study is the percent change from baseline in total body weight at 68 weeks. The key secondary endpoints are total fat mass, total lean mass, physical function (stair climb test), mobility disability assessment, bone mineral density, and patient reported outcome questionnaires for physical function, HbA1c, and insulin resistance. Results of an interim analysis assessing lean body mass and fat mass as measured by DXA after patients have completed 32 weeks is expected in the first quarter of calendar year 2027. Final topline clinical data is expected in the fourth qu", "date_published": "2026-08-10T10:30:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:2310889673cfd81077ce3366a28ff81643320d6c91119a6aec032a4566d61440", "url": "https://finance.yahoo.com/healthcare/articles/scholar-rock-holding-says-apitegromab-091940105.html", "external_url": "https://finance.yahoo.com/healthcare/articles/scholar-rock-holding-says-apitegromab-091940105.html", "title": "Update: Scholar Rock Holding Says Apitegromab BLA Review Stays on Track for September 30 PDUFA Date", "content_text": "(Updates with day of announcement in first paragraph, Novo Nordisk's affiliation in the second paragraph, and latest stock moves in the fourth paragraph.)Scholar Rock Holding (SRRK) said Friday that the FDA review of its apitegromab Biologics License Application for spinal Silver Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade now", "date_published": "2026-08-10T09:19:40+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:fbb7ced15990faaefa3aa8792f0b86b14e77ed1a18ae7e058654502f3b8d1ebc", "url": "https://finance.yahoo.com/healthcare/articles/beltone-illuminate-hearing-aids-automatically-070000511.html", "external_url": "https://finance.yahoo.com/healthcare/articles/beltone-illuminate-hearing-aids-automatically-070000511.html", "title": "New Beltone Illuminate Hearing Aids Automatically Adapt to Noise, Helping People Hear More Clearly in Everyday Life", "content_text": "Premium hearing aids' technological advancement prioritizes what users want to hear \u2013 clearly in noisy situations CHICAGO, Aug. 10, 2026 /PRNewswire/ -- . Following conversations in noisy restaurants, family gatherings, and other busy environments can be one of the biggest challenges for people with hearing loss. To help people hear conversations more clearly, Beltone, a global leader in hearing technology, announced Beltone Illuminate\u2122, a new family of premium hearing aids designed to deliver the world's best hearing in noise. 1-4Beltone Logo Beltone Illuminate\u2122 combines the world's most accu", "date_published": "2026-08-10T07:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "GN"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "GN", "name": "GN Store Nord A/S", "sentiment_url": "https://sharemaestro.com/sentiment/4eb8be51-7272-4e7f-b316-ac4d4ae1f9d9/"}]}}, {"id": "source:c20b0243a7a167658a7d7be160907b68671f52652be55c611c118b9ae1841042", "url": "https://finance.yahoo.com/m/bd14b29c-18a2-3bb0-930e-e50923390400/nvidia%2C-eli-lilly%2C-and-disney.html", "external_url": "https://finance.yahoo.com/m/bd14b29c-18a2-3bb0-930e-e50923390400/nvidia%2C-eli-lilly%2C-and-disney.html", "title": "Nvidia, Eli Lilly, and Disney Show It\u2019s Time to Back the Top Dogs", "content_text": "Investors are still skittish enough that they only want to buy proven winners, so backing the favorite is a smart strategy right now. Continue Reading", "date_published": "2026-08-10T05:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:0cbf687fb10fcaed0e28c35a1790168789b12677e107c3d88cdf2a2c02e06c97", "url": "https://finance.yahoo.com/healthcare/articles/ozempic-50-month-amazon-pharmacy-013108263.html", "external_url": "https://finance.yahoo.com/healthcare/articles/ozempic-50-month-amazon-pharmacy-013108263.html", "title": "Ozempic For $50 a Month? Amazon Pharmacy Rolls Out Cheap Weight-Loss Drugs for Medicare Patients", "content_text": "Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Amazon.com Inc.'s Amazon Pharmacy will offer eligible Medicare beneficiaries weight-loss drugs for $50 per month through a new federal program aimed at expanding access. The company announced on Thursday that the service would automate eligibility checks, prior authorizations, and billing, while providing home delivery and in-store pickup to streamline access. Amazon Pharmacy will begin enrollment for eligible patients after they add their insurance and Medicare information and their clinician submits an electronic prescription. The U.S. Medicare bridge program, launched last month, lets eligible beneficiaries access Novo Nordisk A/S's (injection or pill) and Eli Lilly & Co's four-dose Zepbound KwikPen injection and Foundayo pill through the end of 2027. However, it does not cover single-dose Zepbound vials or pens. Don't Miss: A single bad hire can set a startup back years. Here are the 5 hires founders most often misjudge \u2014 and why Still Learning the Market? These 50 Must-Know Terms Can Help You Catch Up Fast Amazon Pharmacy said most patients in its Bridge Program received prior authorization decisions in under 24 hours, significantly faster than the 72-hour timeframe permitted under the Medicare Bridge Program, according to Vice President Tanvi Patel. The company said that same-day delivery is now available in more than 3,100 U.S. cities and towns and is expected to expand to nearly 4,500 locations by the end of 2026. The company added that many submitted claims have already been fulfilled through completed orders. GLP-1 Becomes a Retail Battleground In April, Amazon expanded into the weight-loss market with a new GLP-1 management program through Amazon One Medical. The service integrates virtual and in-person care, prescription management, and pharmacy fulfillment to make obesity treatment more accessible and support long-term weight management. The pharmacy stated that it would offer GLP-1 weight-loss medications, including Wegovy and newer oral options. See Also: Avoid the #1 Investing Mistake: How Your 'Safe' Holdings Could Be Costing You Big Time Eric Bormel, managing director specializing in digital healthcare at Solomon Partners' healthcare group told CNBC, \"Retailers are betting that if they can become the front door for obesity care, they'll earn a relationship that extends far beyond a single GLP-1 prescription.\" Retailers are using direct-to-consumer (DTC) GLP-1 programs primarily to attract customers, while placing greater value on the broader healthcare ecosystem around the drugs as GLP-1 medication prices continue to decline, Bormel said. Story Continues Experts also expect major retailers and pharmacy chains like CVS Health Corp., Walmart Inc. and Costco Wholesale Corp. to also benefit from the trend. Image via Shutterstock Read Next: Skip the Regrets: The Essential Retirement Tips Experts Wish Everyone Knew Earlier. Think you're saving enough for your kids? You might be dangerously off \u2014 see why Building Wealth Across More Than Just the Market Building a resilient portfolio means thinking beyond a single asset or market trend. Economic cycles shift, sectors rise and fall, and no one investment performs well in every environment. That's why many investors look to diversify with platforms that provide access to real estate, fixed-income opportunities, precious metals, and even self-directed retirement accounts. By spreading exposure across multiple asset classes, it becomes easier to manage risk, capture steady returns, and create long-term wealth that isn't tied to the fortunes of just one company or industry. Arrived Backed by Jeff Bezos, Arrived Homes makes real estate investing accessible with a low barrier to entry. Investors can buy fractional shares of single-family rentals and vacation homes starting with as little as $100. This allows everyday investors to diversify into real estate, collect rental in", "date_published": "2026-08-10T01:31:08+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:c5ceeddf376f383e3bd1d749e29bf2d2c7f5806e59876f0ac09251247e7e9b6b", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-cpse-novo-b-231020183.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-cpse-novo-b-231020183.html", "title": "Novo Nordisk (CPSE:NOVO B) Wins Dutch Injunction Over Compounded Semaglutide Spray", "content_text": "Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Novo Nordisk (CPSE:NOVO B) secured a Dutch court injunction against Ceban Ziekenhuisfarmacie over an unapproved compounded semaglutide nasal spray. The ruling blocks production and distribution of the compounded nasal spray in the Netherlands for infringing Novo Nordisk's semaglutide patent. The decision reinforces Novo Nordisk's intellectual property position around Wegovy, Ozempic and Rybelsus and limits non approved competitor versions. Patent enforcement around key obesity and", "date_published": "2026-08-08T23:10:20+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:d0da1f151a3d80017cceb1f7ae0a18d84628e12c66aaabafd44fc2f9efda376a", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-q2-earnings-call-220350961.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-q2-earnings-call-220350961.html", "title": "Novo Nordisk A/S Q2 Earnings Call Highlights", "content_text": "Key Points Interested in Novo Nordisk A/S? Here are five stocks we like better. Novo Nordisk raised its 2026 outlook after a better-than-expected start to the year, reporting Q2 adjusted sales of DKK 78.5 billion and 7% growth at constant exchange rates. However, lower realized prices, manufacturing costs and currency effects reduced the adjusted gross margin to 78.2% from 82.7%. Oral Wegovy drove obesity-treatment momentum. The U.S. pill surpassed 5 million prescriptions and captured about 90% of the oral obesity-drug market, while roughly 80% of users were new to GLP-1 treatments; internatio", "date_published": "2026-08-08T22:03:50+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:66c735ba5a026780051e956a1f80ecf50a4959ba1b45f56a1a2e16685446ab17", "url": "https://finance.yahoo.com/healthcare/articles/scholar-rock-announces-fda-review-202000956.html", "external_url": "https://finance.yahoo.com/healthcare/articles/scholar-rock-announces-fda-review-202000956.html", "title": "Scholar Rock Announces FDA Review of Apitegromab Biologics License Application (BLA) for Spinal Muscular Atrophy (SMA) to Progress with Second Fill-Finish Facility; Approval Decision Anticipated by September 30, 2026 Action Date", "content_text": "Today, August 7, 2026, Scholar Rock received customer notification from Catalent Indiana LLC (part of Novo Nordisk) that FDA classified the April 2026 site inspection of Catalent Indiana fill-finish facility as Official Action Indicated (OAI) Scholar Rock continuing to collaborate closely with FDA and under their guidance, will remove Catalent Indiana fill-finish facility from apitegromab BLA FDA review of second fill-finish facility progressing; Data package for FDA review of second fill-finish facility, as agreed to during March 2026 Type C meeting, has been submitted in advance of agreed upon timeline Robust supply of apitegromab commercial vials from second fill-finish facility available upon FDA approval Scholar Rock is prepared for U.S. apitegromab launch immediately upon FDA approval, which may be granted at any time through September 30, 2026 Prescription Drug User Fee Act (PDUFA) date Company engaging with European Medicines Agency (EMA) on next steps to include Scholar Rock's second fill-finish facility in apitegromab Marketing Authorisation Application (MAA) CAMBRIDGE, Mass., August 07, 2026--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to improving the lives of patients with rare, severe, and debilitating neuromuscular diseases by applying its world-leading platform in myostatin biology, today announced that the FDA review of the apitegromab Biologics License Application (BLA) for the treatment of children and adults with spinal muscular atrophy (SMA) is progressing with the Company's second fill-finish facility. The BLA remains on track for potential FDA approval by the September 30, 2026 Prescription Drug User Free Act (PDUFA) action date. \"We continue to be very pleased with our second fill-finish facility,\" said David L. Hallal, Board Chair and Chief Executive Officer of Scholar Rock. \"The data package that we agreed upon with the FDA at our Type C meeting has been submitted, the FDA review of the facility is advancing, robust supply for commercialization is ready and awaiting packaging and labeling at a third-party site, and importantly, the facility has demonstrated a strong track record of compliance, including recent successful FDA and EMA inspections. As we work closely with the FDA on the final steps of the apitegromab BLA review process, we are ready to bring the world's first muscle-targeted treatment to children and adults with SMA.\" Scholar Rock's apitegromab BLA submission in March 2026 included two fill-finish facilities, in alignment with FDA guidance. These facilities were Catalent Indiana LLC (part of Novo Nordisk) and a second facility, which provided two independent paths to a potential FDA approval. The Company received a customer notification from Catalent Indiana on August 7, 2026 that the FDA has classified the April 2026 site inspection of Catalent Indiana as Official Action Indicated (OAI). Scholar Rock will continue to collaborate closely with the FDA and under their guidance, will remove Catalent Indiana from the apitegromab BLA. FDA review of the apitegromab BLA will progress solely with the second fill-finish facility. Story Continues At the March 2026 Type C meeting, FDA and Scholar Rock agreed to the data package required for FDA review of the second fill-finish facility. That data package was submitted in advance of the agreed upon timeline, and Agency review of the data is progressing well. Robust supply from the second fill-finish facility is available, with vials from that facility on site at a third-party provider awaiting packaging and labeling for commercialization upon FDA approval. The second fill-finish facility for apitegromab is a U.S.-based facility producing numerous commercial products and it is in good standing with FDA and EMA. In Europe, Scholar Rock continues to engage with the European Medicines Agency (EMA) on next steps to include the Company's second fill-finish facility in the apitegromab Marketing Authorisation A", "date_published": "2026-08-07T20:20:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}, {"id": "source:360e8745ede5b53f3f80fcffde547d963f8e9715109f76f34e8b9f62aa95aa02", "url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-stock-rises-glp-195231835.html", "external_url": "https://finance.yahoo.com/healthcare/articles/novo-nordisk-stock-rises-glp-195231835.html", "title": "Novo Nordisk Stock Rises After GLP-1 Antitrust Win", "content_text": "This article first appeared on GuruFocus. Novo Nordisk (NYSE:NVO), the Danish pharmaceutical giant behind Ozempic and Wegovy, edged nearly 2% higher during Friday's U.S. regular session after a federal judge threw out an antitrust lawsuit against Novo and Eli Lilly (NYSE:LLY). According to Reuters, the case was filed by Strive Specialties, which claimed the drugmakers unfairly limited access to compounded GLP-1 weight-loss drugs through exclusive telehealth partnerships. Warning! GuruFocus has detected 4 Warning Sign with NVO. Is NVO fairly valued? Test your thesis with our free DCF calculator", "date_published": "2026-08-07T19:52:31+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Regulatory and legal", "NOVO-B"], "_sharemaestro": {"country": "Denmark", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NOVO-B", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/1fd8285a-521c-4704-8a16-0cb6f4e59c1f/"}]}}]}